Nicolet Advisory Services’s Alaunos Therapeutics TCRT Stock Holding History

Nicolet Advisory Services’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-143	Closed	-$2.82K	–	354
2023 Q4	$2.82K	Hold	143	–	–	﹤0.01%	320
2023 Q3	$2.36K	Hold	143	–	–	﹤0.01%	315
2023 Q2	$10.4K	Hold	143	–	–	﹤0.01%	308
2023 Q1	$12.9K	Hold	143	–	–	﹤0.01%	283
2022 Q4	$15.6K	Hold	143	–	–	﹤0.01%	239
2022 Q3	$31K	Hold	143	–	–	0.01%	191
2022 Q2	$30K	Hold	143	–	–	﹤0.01%	184
2022 Q1	$11K	Hold	143	–	–	﹤0.01%	201
2021 Q4	$23K	Hold	143	–	–	﹤0.01%	206
2021 Q3	$39K	Hold	143	–	–	﹤0.01%	201
2021 Q2	$57K	Hold	143	–	–	0.01%	187
2021 Q1	$77K	Sell	143 -7	-5%	-$4.36K	0.01%	172
2020 Q4	$57K	Hold	150	–	–	0.01%	172
2020 Q3	$57K	Buy	+150	New	+$66.3K	0.01%	170

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Nicolet Advisory Services's TCRT Position: Q1 2024 in Review

Nicolet Advisory Services sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 143 shares — an estimated $2.82K sold.

Nicolet Advisory Services first reported a position in TCRT in Q3 2020 and held it in 14 quarters. The position peaked at $77K in Q1 2021. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Nicolet Advisory Services reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Nicolet Advisory Services sold 143 Alaunos Therapeutics shares in Q1 2024, an estimated $2.82K.
Nicolet Advisory Services first reported a position in Alaunos Therapeutics in Q3 2020 and held it in 14 quarters.
Nicolet Advisory Services's Alaunos Therapeutics position peaked at $77K in Q1 2021.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Nicolet Advisory Services's 13F filing for Q1 2024, filed 10 May 2024.